Validation of Hepatoma Arterial Embolization Prognostic (HAP) Score in Egyptian Patients with Hepatocellular Carcinoma

Mohamed Kohla¹, Gasser El-Azab¹, Asmaa Gomaa¹, Mohamed Abbasy¹, Mai Abozeid¹, Asmaa Abdelhaie¹ and Mohamed Saied Abdelgawad²

¹Hepatology and Gastroenterology department, National Liver institute, Menoufia University, Shebin El-Kom, Egypt.
²Diagnostic and Interventional Radiology and medical imaging department, National Liver institute, Menoufia University, Shebin El-Kom, Egypt.

Correspondence: Mohamed Ahmed Samy Kohla, MD, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt, Tel: +201111047684.

Received: 05 July 2019; Accepted: 29 July 2019

Citation: Mohamed Kohla, Gasser El-Azab, Asmaa Gomaa, et al. Validation of Hepatoma Arterial Embolization Prognostic (HAP) Score in Egyptian Patients with Hepatocellular Carcinoma. Gastroint Hepatol Dig Dis. 2019; 2(2): 1-5.

ABSTRACT

Background: Hepatoma Arterial Embolization prognostic (HAP) score has recently emerged as an overall survival predictor for hepatocellular carcinoma (HCC) patients after treatment with transarterial chemoembolisation (TACE). It depends on serum bilirubin, albumin, alpha-fetoprotein (AFP) and tumor size. We evaluated the utility and validity of HAP score in a cohort of Egyptian patients with HCC who underwent TACE.

Methods: Our study included 416 Egyptian patients with HCC who underwent TACE at National Liver institute, Menoufia University, Egypt from January 2013 to May 2015. Child-Turcotte-Pugh (CTP), BCLC Staging as well as HAP score were calculated. Overall survival was assessed with a minimum follow up period of 12 months.

Results: Patients were mainly males (83.7 %) with a mean age of 58 ± 8.1 years, 267 (64.9%) patients had Child A cirrhosis, 143 (34.7%) had Child B cirrhosis and only one (0.2%) patient had Child C cirrhosis. Ten patients (2.4%) were in BCLC stage 0, 63 patients (15.1%) were in BCLC stage A, 335 patients (80.5%) were in BCLC stage B, 7 patients (1.7%) were in BCLC stage C and only one patient (0.2%) was in BCLC stage D. Fifty-one patients (12.3%) had a HAP score of 0, 129 (31%) had a score of 1, 164 (39.4%) had a HAP score of 2 and 72 (17.3%) had a HAP score of >2. Patients with HAP 0, HAP 1, HAP 2 and HAP >2 had a median survival of 53, 23, 22, 14 months respectively, showing a significantly shorter survival with more advanced score. Survival probability was 37.2%, 26.1%, 9.2% and 7.3% for patients with HAP score 0, 1, 2 and >2 respectively, with a P value 0.001.

Conclusion: HAP score is useful in survival prediction after TACE in HCC patients and can be used for proper patient selection to improve outcome after TACE.

Keywords: Hepatoma Arterial Embolization, Hepatocellular Carcinoma, Prognostic score, Transarterial chemoembolisation.

Introduction

Worldwide, hepatocellular carcinoma (HCC) is the fifth of the most frequent cancers and the second of the leading causes of deaths due to cancer in males [1]. In women, it is considered the seventh most common cancer and the sixth of the leading causes of deaths related to cancer [2]. In Egypt, the frequency of liver-related cancers in hospital-based studies is increasing over time [3]. Several staging systems were developed for classification of HCC patients but none has specifically been developed for predicting outcomes of therapy [4]. Transarterial chemoembolization (TACE) and bland Transarterial embolization (TEA) has become the most popular modality for treatment of unresectable hepatocellular carcinoma (HCC) [5-7]. However, patients who are candidate for TACE or TEA includes a wide spectrum in terms of liver function and extent of tumor, and this may explain the large differences in individual series reported survival [8]. Kadalayil and his colleagues identified a simple, pragmatic, and reliable prognostic system that was based on the four most statistically significant predictors of overall survival (OS) on multivariate analysis (albumin, bilirubin, AFP and tumor size). Patients were assigned one point for each of the
Our study evaluated the validity and utility of Hepatoma Arterial Embolization prognostic score (HAP Score) to predict survival after TACE in Egyptian patients with HCC.

Patients and Methods
Patients with a confirmed diagnosis of HCC who attended the oncology clinic at National Liver Institute, Menoufia University, Egypt, from January 2013 to May 2015 were identified. A total of 416 patients who received TACE as the primary treatment were enrolled. All patients were subjected to full history taking including patient’s demographics, etiology of liver disease, performance status and complete laboratory tests including complete blood count, International Normalized Ratio (INR), liver & renal function tests, serum AFP level, hepatitis markers (HCV Ab, HBsAg, HBc total Ab) and HCV RNA PCR. Abdominal ultrasonography, triphasic abdominal CT and/or dynamic MRI were performed stressing on liver and spleen size, texture, focal lesion, portal vein diameter and patency and presence of ascites. BCLC staging was assessed. HAP, Child Turcotte Pugh (CTP) as well as Model for End stage Liver disease (MELD) scores were calculated.

Patients were followed up from the time of enrollment to the date of death or date of data collection if they remained alive with minimum follow up period of 1 year. Overall survival (OS) was determined. OS is defined as the time from the date of TACE initiation until the date of death or last follow-up.

Diagnosis and definition: The diagnosis of HCC was based on the presence of hepatic focal lesion(s) larger than 1 cm in abdominal ultrasonography that showed the characteristic vascular enhancement pattern of HCC (hypervascular in the arterial phase and showing washout in the portal venous or delayed phase) with a 4-phase multidetector CT scan or a contrast enhanced dynamic MRI. For patients with atypical vascular enhancement pattern, a second contrast enhanced dynamic imaging or histopathological confirmation was needed [10-11].

HAP Score was calculated for all patients within three days of the procedure. Patients were assigned one point for each of four parameters (Albumin < 3.6 g/dl, AFP > 400 ng/ml, Bilirubin > 1 mg/dl, Size of the largest tumor > 7 cm). The HAP score was defined as the sum of these values, accordingly patients were classified into 4 risk groups according to their HAP score, HAP A, B, C and D (scores 0, 1, 2 and >2 respectively) [9].

Qualitative data were expressed as frequency and percent. Patient and tumor characteristics were assessed and expressed as Median (interquartile range [IQR]) or n (%). Survival analysis was estimated by the Kaplan–Meier method. Median survival times and their 95% confidence intervals (CIs) were reported wherever possible. The survival difference between each group was assessed using the log-rank test. Cox regression model was used to give adjusted hazard ratio and 95% confidence interval of the effect of the different risk factors. Survival probability: the number of patients that survived beyond specific time. Survival probability calculated at 2 years for HAP score classes. P-value was considered statistically significant when it is less than 0.05.

Results
A total of four hundred and sixteen patients who received TACE were included in our study. Most of them were males (83.7% male, 16.3% female). Their Mean age was 58.7 ± 8.1 years, ranging from 32 to 83 years old. Two hundred and fourteen (51.4%) patients were smokers, 111(26.6%) were diabetics and 88 (21.2%) were hypertensive. Only 3.8% of our patients received antiviral treatment. Table 1 summarizes the Lab data of the studied groups.

The higher proportion of our cohort was Child Pugh grade A, 271 (65.1%) patients, while 144 patients (34.6%) were Child B and 1 patient (0.2%) was Child C at presentation. Their MELD score ranged from 6 to 20, Mean ± SD (10.33 ± 2.8). Two hundred thirteen of our patients had single focal lesion, while 203 had multiple focal lesions. According to BCLC staging systems, ten patients (2.4%) were in the very early stage (BCLC 0), 63 patients (15.1%) were in the early stage (BCLC A), 335 patients (80.5%) were in the intermediate stage (BCLC B), 7 patients (1.7%) were in the advanced stage (BCLC C) and only one patient (0.2%) was in the terminal stage (BCLC D). HAP Score just prior to the procedure was calculated for all patients. Fifty-one patients (12.3%) were HAP A, 129 (31.0%) were HAP B, 164 (39.4%) were HAP C and 72 (17.3%) were HAP D.

### Statistical analysis
The analysis was done with Statistical Package for Social Sciences (SPSS version 20.0; IBM Corp., Armonk, NY). Quantitative data were shown as mean, standard deviation (SD) and range. Qualitative data were expressed as frequency and percent. Patient and tumor characteristics were assessed and expressed as Median (interquartile range [IQR]) or n (%). Survival analysis was estimated by the Kaplan–Meier method. Median survival times and their 95% confidence intervals (CIs) were reported wherever possible. The survival difference between each group was assessed using the log-rank test. Cox regression model was used to give adjusted hazard ratio and 95% confidence interval of the effect of the different risk factors. Survival probability: the number of patients that survived beyond specific time. Survival probability calculated at 2 years for HAP score classes. P-value was considered statistically significant when it is less than 0.05.

### Lab data

| Lab data                  | Mean ± SD Range          |
|---------------------------|--------------------------|
| HbA (no = 416)            | Negative                 |
|                           | 107                      | 25.7                     |
|                           | Not available            | 309                      | 74.3                     |
| HCV Ab (no=416)           | Positive                 |
|                           | 215                      | 51.7                     |
|                           | Not available            | 198                      | 47.6                     |
| ALT (IU/ml)               | 52.2 ± 34.4, 5.0 - 206   |
| AST (IU/ml)               | 65.8 ± 46.3, 4 - 360     |
| Alkaline Phosphatase (IU/ml) | 137.4 ± 82.1, 10.0 - 350 |
| GGT (IU/ml)               | 101.9 ± 57.8, 34 - 211   |
### Table 1: Lab data of the studied groups.

| Parameter                  | Mean ± Standard Deviation | Range          |
|----------------------------|---------------------------|----------------|
| Hb (mg/dl)                | 12.5 ± 1.8                | 7.0 – 17.4     |
| WBCs (/cmm)               | 5.5 ± 2.6                 | 1.60 - 22      |
| Platelets (/cmm)          | 115.9 ± 68.4              | 33.0 - 622     |
| Total Bilirubin (mg/dl)   | 1.40 ± 0.7                | 0.30 - 4.2     |
| Direct Bilirubin (mg/dl)  | 0.66 ± 0.51               | 0.09 – 3.0     |
| Albumin (g/dl)            | 3.4 ± 2.3                 | 1.60 – 4.9     |
| Prothrombin (% C)         | 75.5 ± 15.8               | 0.84 - 108     |
| INR                       | 1.2 ± 0.2                 | 0.80 – 2.0     |
| Urea                      | 34.7 ± 15.1               | 11.0 - 127     |
| Creatinine (mg/dl)        | 0.91 ± 0.26               | 0.30 - 2.40    |
| AFP (IU/ml)               | 1471.0 ± 7826.9           | 1 – 106370     |

### Table 2: Comparison of HAP score stages regarding mean and median survival.

| HAP Score | Mean (months) | Median (months) |
|-----------|---------------|-----------------|
| A (0)     | 49.16         | 53              |
| B (1)     | 34.20         | 23              |
| C (2)     | 22.44         | 22              |
| D (>2)    | 19.63         | 14              |
| Overall   | 31.98         | 21              |

On the other hand, there was no statistically significant difference between patients with single versus multiple focal lesions regarding survival (p value = 0.450) (Table 3, Figure 2). In univariate survival analysis, age, serum bilirubin, serum albumin, serum AFP level and tumor size were the factors associated with prognosis (all p values < 0.05). Cox regression multivariate analysis revealed that age is a statistically significant independent factor affecting patient survival with p value < 0.00 and hazard ratio (HR=1.1). Also, AFP>400, serum albumin <3.6, bilirubin >1, tumor size >7 cm are independent predictors of patient survival with p value (0.01, 0.02, <0.001, <0.001 respectively and HR 95% CI (1.48, 1.53, 1.78, 1.76 respectively) (Table 4).

### Table 3: Comparison of Mean and median survival time of patients classified according to tumor number (single or multiple).

| No of focal lesions | Estimate | Std. Error | 95% Confidence Interval | Estimate | Std. Error |
|---------------------|----------|------------|-------------------------|----------|------------|
| Multiple            | 25.910   | 2.072      | 21.850 - 29.971         | 22.000   | 2.401      |
| Single              | 37.455   | 4.272      | 29.083 - 45.828         | 21.000   | 1.353      |
| Overall             | 31.989   | 2.813      | 26.476 - 37.503         | 21.000   | 1.303      |

### Figure 1: Comparison of survival between HAP score stages.

### Discussion

Staging systems are used to define HCC prognosis and allocate treatment. The best staging system can stratify patients according to their survival time and is useful and reliable for comparing the
The present study was designed to evaluate validity and utility of Hepatoma Arterial Embolization score (HAP score) in Egyptian patients with HCC. Our study was a retrospective study, conducted on 416 patients who attended the HCC clinic at National Liver Institute, from January 2013 up to May 2015 and underwent TACE. Demographically, most of our HCC patients were in their 5th decade of life with a mean age (58.7 ± 8.1) which is the expected time needed for development of HCC on top of cirrhotic patients with progressively increased incidence of HCC occurrence with advanced age in all populations, reaching a peak at 70 years [14]. HCC was more prevalent in males in this study (83.7% males versus 16.3% females) which comes in accordance with most HCC studies which suggested that the relatively low incidence of HCC in females during their reproductive years might be due to hepatic production of high levels of 2-methoxyestradiol. Consequently, the growth of hepatocellular carcinoma in females is delayed significantly as compared to males [15].

HAP score was calculated for patients: 12.3% were HAP A, 31.0% were HAP B, 39.4% were HAP C, 17.3% were HAP D. Patients followed up for survival for at least one year, median survival for HAP score A, B, C, D was found: 53.0, 23.0, 22.0, 14.0 months respectively with overall median survival 21 months. Comparison of survival probability at 2 years among HAP score stages was found: 37.2%, 26.1%, 9.2%, 7.3% for HAP score A, B, C and D respectively, so there was significantly statistical difference among HAP score classes regarding probability of survival (P value 0.001). This was in agreement with a study in the United Kingdom on 431 patients with HCC who received TACE at a liver centre between 2005 and 2012. They reported that progression free survival (PFS) was 30.3, 19.5, 15, 6.2 months for HAP score A, B, C, D respectively with p value < 0.005 and concluded that there was a trend to longer survival with lower HAP scores and the HAP score predicts outcomes in patients with HCC undergoing TACE/TAE [16]. This is also in agreement with Pinato and his colleagues in a study on 660 patients from Japan and Korea that integrated and compared the assessment for re-treatment with TACE (ART) and HAP scores for their accuracy in prediction of overall survival (OS). They found that ART and HAP scores are independent predictors of OS (p<0.01) with a better prognostic accuracy of HAP over ART score [17].

Patients were classified according to size of focal lesion or the largest lesion if the patient had 2 or more focal lesions into <7 cm or ≥7 cm. There was statistically significant difference between patients with size of largest ≥7 cm and patients with size of largest tumor <7 cm regarding survival (p value < 0.001). This results are in agreement with Grieco et al. who found in multivariate analysis that tumor diameter <3 cm, absence of PVT, low AFP and low bilirubin level were significantly independent predictor of survival in patients with early-intermediate HCC having nonsurgical therapy [19].

There was statistically significant difference between patients with serum albumin < 3.6 and patients with serum albumin ≥ 3.6 regarding survival (p value = 0.02). These results was in agreement with Ikeda et al. who found that HCC patients treated by transcatheter arterial Embolization with serum albumin ≥3.5 g/dl, age < 60 years, α-fetoprotein < 400 ng/ml were significantly associated with favorable survival [20]. Cox regression analysis clarified that age is statistically significant independent factor affecting patient survival (P value < 0.001), (HR = 1.1). When performing statistical analysis according to tumor number; we found that there was no statistically significant difference between patients with single and patients with multiple focal lesions regarding probability of survival (p value = 0.450). This is in disagreement with Park et al. in a study on 280 Korean patients with HCC treated with TACE; tumor number ≥ 2 was selected as an independent unfavorable prognostic factor. So, a modified HAP-II (mHAP-II) score was established by adding tumor number ≥ 2 [21].

As the four components of HAP scoring system (albumin, bilirubin, AFP and tumor size) were significantly affecting survival in this study, while tumor number showed no impact; the original HAP score is more accurate in our cohort than both versions of modified score. HAP score was assessed by Kohla et al., in prediction of hepatic decompensation after TACE and they found no statistically significant difference between HAP score classes this may be due to small number of patients (102 patients), but univariate analysis showed that low baseline albumin and high AFP was predictive of hepatic decompensation after TACE [22].

Conclusion
In conclusion, HAP score is a useful tool to predict survival...
after TACE in Egyptian patient with intermediate stage HCC predominantly HCV induced cirrhosis.

Acknowledgments
We thank the oncology clinic team at the National liver institute, Menoufia University, Egypt for their help & support.

References
1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin .2011; 61: 69-90.
2. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014; 60: 1767-1775.
3. El-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005; 11: 5193-5198.
4. Cammà C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther. 2008; 28: 62-75.
5. Shi M, Chen JA, Lin XJ, et al. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol. 2010; 16: 264-269.
6. Sacco R, Bertini M, Petruzzi P, et al. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol. 2009; 15: 1843-1848.
7. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4: 439-474.
8. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011; 37: 212-220.
9. Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013; 24: 2565-2570.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
11. Llovet JM, Dureux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943.
12. Chung H, Kudo M, Takahashi S, et al. Review of current staging systems for hepatocellular carcinoma. Hepatol Res. 2007; 37: S210-215.
13. Zhong JH, Xiang BD, Gong WF, et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One. 2013; 8: e68193.
14. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340: 745-750.
15. Lui WY, Lin HL, Chau GY. Male predominance in hepatocellular carcinoma: new insight and a possible therapeutic alternative. Med Hypotheses. 2000; 55: 348-350.
16. Aravind P, Thillai K, Sarker D, et al. Prognostic significance of the hepatoma arterial embolization prognostic (HAP) score in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization: A single centre experience. J Clin Oncol. 2017; 34: e15617.
17. Pinato DJ, Arizumi T, Jang JW, et al. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget. 2016; 7: 44705-44718.
18. Pinato DJ, Arizumi T, Allara E, et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol. 2015; 13: 1204-1208.
19. Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005; 54: 411-418.
20. Ikeda M, Okada S, Yamamoto S, et al. Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Jpn J Clin Oncol. 2002; 32: 455-460.
21. Park Y, Kim SU, Kim BK, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016; 36: 100-107.
22. Kohla MA, Abu Zeid MI, Al-Warraky M, et al. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterol. 2015; 2: e00032.